The purpose of this study is to examine whether the inhibition of aldosterone will result in lower excretion of protein via urine. The hypothesis is that if loss of protein is lowered, progression of renal disease with be slower than otherwise expected.
Patients with chronic renal disease are likely to progress to end stage renal disease with the need for renal replacement therapy. It is accepted that proteinuria is a surrogate measurement for progression. If proteinuria can be lowered we hope to prolong patients pre-dialysis phase. Our theory is that aldosterone inhibition will lead to this. For a period of 8 weeks patients will be randomized to either aldosterone receptor inhibition with the drug eplerenone or control without. Blood pressures will be kept at the same level using other drugs.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
42
Once daily administration for 8 weeks and 8 weeks control.
Rigshospitalet, Blegdamsvej 9
Copenhagen, Denmark
Herlev Hospital
Herlev, Denmark
Proteinuria reduction
Time frame: bi-monthly
Evaluating blood pressure response and hyperkalaemia after aldosterone inhibition.
Time frame: weekly
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.